Renal Disease Market Research Report - Forecast till 2030

Renal Disease Market: Information by Disease Type (Chronic Kidney Disease and End-Stage Renal Disease (ESRD)), by Treatment Type (Dialysis, Medication and Kidney Transplantation), by End User (Dialysis Centers, Hospital & Clinics, and Research and Academic Institutes) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/2289-CR | 157 Pages | Published By Kinjoll Dey on February 2021         

Renal Disease Market Speak to Analyst Request a Free Sample

Renal Disease Market Overview

The renal disease market is projected to reach USD 89,070 Million by 2030 at 11.20% CAGR during the forecast period 2022-2030. When the kidney cannot function properly, this renal disease occurs. Hence, it is also known as kidney disease. Depending upon the different numerous conditions, different types of symptoms, and signs, different types of kidney diseases are formed. 

In this vast population, most of the people are suffering from renal disease, diabetes, and hypertension. The growth of geriatric people is expected to increases the chronic kidney disease market growth. Apart, the healthcare cost and stringent regulatory policies are going to be increasing.

COVID-19 Analysis:

COVID-19 pandemic has everyone’s life in different ways. Due to the government regulations and lockdowns, people stayed in the home itself, and hence the demand for home dialysis increases. Most of the affected people of COVID-19 are people suffering from diabetes and ESRD compared to healthy people. The condition with reduced kidney function leads to chronic kidney disease which may lead to end-stage renal disease (ESRD). 

Worldwide, all countries are taking necessary steps to ensure the safety of the patients amid the crisis. Additionally, the government issued the guidelines and Interim Additional Guidance for Infection Prevention and Control (IPC) recommendations for the patients who are suspected and confirmed of the coronavirus disease.

Market Dynamics:


Diagnosis of Blood Test for high growth over the forecast period

A blood test is a major test for the diagnosis of kidney disease which shows detailed information about kidneys working conditions. Due to the increase of Chronic Kidney Disease (CKD) the demand for blood tests is expected to increase. Moreover, the ESRD (End-Stage Renal Disease) is also increasing at a significant rate.

 In 2017, it is recorded that 697.5 million people with CKD struggle. After causing CKD, it may develop and lead to ESRD which tends to kidney failure. In Singapore, from 2007 to 2017 the prevalence of CKD increases from 12% to 17% and is further expected to increase by approximately 24% by 2035.  Due to the rise of chronic kidney disease, the market is expected to be high over the forecast period. An increasing number of patients with hypertension and diabetes, high prevalence of ESRD, and rapid growth in the geriatric population are major drivers of the market.


Rise of Healthcare cost and stringent regulatory policies

By increasing the cost of the healthcare sector and stringent regulatory policies are the restraints of the market growth. By reducing the cost of the healthcare sector, it may be expected to increase the growth of renal disease treatment.


Expansion in Developing Economies

The developing and developed countries launched advanced technological products in the market to reduce the increase in renal failures. This new expansion increases the end-stage renal disease market growth.


Reduction of the cost over the healthcare sector is the major challenge of the end-stage market growth.

Technology Analysis

The technologically advanced products like low maintenance dialysis equipment for diagnosis of Chronic Kidney Disease and artificial kidney helps to the growth of the end-stage renal disease market.

Study Objectives -

  • To provide detailed information about the renal disease market structure along with various forecast segments and sub-segments.

  • To provide the factors that affecting the end-stage renal disease market growth.

  • To analyze the renal disease market-based porter’s five force analysis, etc.

  • To provide history and forecast revenue segments for the four main geographic countries

  • To provide the country-level analysis of the current renal disease market size and future prospective

  • To provide country-level analysis of the end-stage market growth by region, application, treatment

  • To provide a strategic profile of the key players in the market, analyze their core competencies, and draw a landscape of the renal disease market growth.

  • To track and analyze new product developments, strategic alliances, and research in the global renal disease market.

Segment Overview:

Globally, Renal disease stages have been segmented into two types of diseases like chronic kidney disease and end-stage renal disease.

Based on Treatment Type

The renal disease market is segmented into dialysis, medication, and kidney transplantation. Further dialysis is segmented into peritoneal dialysis, hemodialysis, and wearable artificial kidney for renal disease treatment.

Based on end-users

The renal disease market is segmented into dialysis centers, hospitals &clinics, research, and academic institutes.

Based on Region

Based on the region, the renal disease market is divided into four regions-America, Europe, Asia-Pacific, and the Middle East & Africa. Out of these, America is expected to be the highest market share among the others. Europe is expected to be the second-largest and Asia-Pacific is to be the fastest-growing region in the global market over the forecast period. 

Regional Analysis -

Based on the region, the renal disease market is divided into four main regions- America, Europe, Asia-Pacific, and the Middle East & Africa.

Due to the increasing prevalence of renal disease causes to the geriatric population and the high availability of advanced features in North America, America is expected to the largest market share in the renal disease market. Europe is expected to be the second-largest share of the renal disease market for its high awareness of renal diseases, the government extended recommendations for dialysis, and the elderly population growth. In Europe, there is a rise in demand for diagnostic tests. In 2015, 10% of people are affected by CKD.

Due to the presence of developing economies like India, China, and South Korea, Asia-Pacific is expected to be the fastest-growing region in the market. These countries are highly demandable for the outsourcing of drug manufacturing, clinical trials, and pathology testing. Due to the high prevalence of renal disease in Saudi Arabia, Kuwait, and the UAE, the Middle East & Africa are expected to grow in the market.

Competitive Landscape

The prominent key players in the renal disease market are as follows:

  • Abbott (US)

  • Amgen Inc (US)

  • AstraZeneca (US)

  • Bristol-Myers Squibb Company (US)

  • Hoffmann- La Roche Ltd (Switzerland)

  • Fresenius Medical Care AG & Co., Ltd (Japan)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • Sanofi SA (France) and

  • Teva Pharmaceutical Industries Ltd (Israel)

These key players are focussing on the launch of new developments, innovation, mergers, and acquisitions. Fresenius Medical Care is one of the leading companies that introduce new developments with advanced features.

Recent Developments

  • In October 2016, Teva acquired Anda, Inc. which is a leading distributor of generic pharmaceuticals.

  • In June 2017, Sanofi to strengthen its pharmaceutical business in Morocco and other African countries, Sanofi signed with a Europharma in Morocco.

  • In May 2015, Fresenius introduced a new therapy system multiFiltratePRO which is continuous renal replacement therapy (CRRT) that is used for the treatment of acute kidney failure.

  • In October 2019, Fresenius Medical Care has designated with U.S FDA for its new hemodialysis machine which is used to stop blood clotting without any use of medication. 

Report Overview:

The full report is inclusive of the following:

  • Market Overview

  • COVID-19 Analysis

  • Market Dynamics

  • Technology Analysis

  • Study Objectives

  • Segment Overview

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments

  • Segmentation Table

  • FAQs

Segmentation Table

The research in the segmentation of the renal disease market is done based on treatment, end-users, and region.

By Disease Type

Chronic Kidney Disease, end-stage renal disease

By Treatment Type

Dialysis, medication, and kidney transplantation

By end-user

Dialysis centers, hospitals & clinics, research, and academic institutes

By Region

America, Europe, Asia-Pacific, and Middle-East & Africa

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 89,070 Million
  CAGR   11.20%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Disease Type, Treatment Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott (US), Amgen Inc (US), AstraZeneca (US), Bristol-Myers Squibb Company (US), Hoffmann- La Roche Ltd (Switzerland), Fresenius Medical Care AG & Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi SA (France) and Teva Pharmaceutical Industries Ltd (Israel)
  Key Market Opportunities   Expansion in Developing Economies
  Key Market Drivers   Diagnosis of Blood Test for high growth

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Renal disease market projected to grow at approximately 11.20% CAGR during the assessment period (2022-2030).

The valuation of the renal disease market is estimated to increase to USD 89,070 Million by the end of 2030.

Growth in the prevalence of kidney diseases and the rising government funding for R&D & initiatives to spread the awareness, are major tailwinds pushing the growth of the global renal disease market.

North America holds the largest share in the global renal disease market, followed by Europe and the Asia Pacific, respectively.

Amgen Inc. (US), AstraZeneca (US), Abbott (US), Bristol-Myers Squibb Company (US), Fresenius Medical Care AG & Co. KGaA (UK), Teva Pharmaceutical Industries Ltd (Israel), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Kissei Pharmaceutical Co., Ltd (Japan), Keryx Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), and Sanofi SA (France), are some of the top players operating in the global renal disease market.